Cirrhosis
536
82
97
269
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
53 trials with published results (10%)
Research Maturity
269 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
30 terminated out of 536 trials
90.0%
+3.5% vs benchmark
20%
105 trials in Phase 3/4
20%
53 of 269 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 269 completed trials
Clinical Trials (536)
Decompensation of Cirrhosis and Iron Metabolism
Use of the French Healthcare Insurance Database
mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis
Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis
The Impact of Liver Cirrhosis on Outcomes in Trauma Patients
Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
The Efficacy of Aerobic Exercise Training on ANS and Endothelial Function in Compensated Cirrhosis
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
Timing of Endoscopic Intervention for Acute Variceal Hemorrhage: an RCT
LIFT Intervention in Liver Transplant Candidates
Microplastics, Cirrhosis and Portal Hypertension
Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS